MENOPAUSAL SKIN CARE CONTROL RETINOL CREAM (1%) ELASTAPURE (3MG/ML)


61


Figure 4: Representative microscopic images showing skin sections after various treatments to highlight the presence of specific ECM components using immunostaining. Elastin content is represented in green. Hyaluronic acid content is represented in pink and was obtained via immunostaining of hyaluronic acid binding protein


were further evaluated in an ex vivo study using skin explants obtained from a female donor, aged 47 years old, from abdominoplasty. Skin explants were treated topically on days 0, one and four, and sampled for analysis on day five. The tissue was immobilized, sectioned, and immunostained for the observation and quantification of elastin and hyaluronic acid. The treatment containing the polypeptide consisted of an aqueous solution containing


3mg/ml of the recombinant human elastin. The control tissue was treated with the aqueous solution without the polypeptide. An additional commercially available cosmetic cream containing 1% retinol was tested for reference.


The study reveals a noticeable increase


in key ECM components in the dermis and epidermis following topical treatment with recombinant human elastin (Figure 4). To quantify the presence of these ECM


components, image analysis techniques were applied (cellSens (Olympus) software) and reported as the percentage of the surface of the region of interest occupied by the analyzed ECM component. The results compiled in Figure 5 show that


the topical treatment with the recombinant elastin led to a significant increase of the elastin network in the papillary dermis, with an average increase of 59% relative to control, and an increase of 81% when compared to the


www.personalcaremagazine.com


November 2025 PERSONAL CARE


HYALURONIC ACID


ELASTIN


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107